Earnings call transcript: Cash Converters posts record FY2026 revenue in H2 2026

Cash Converters reported record FY2026 revenue of AUD 429M (+11%) and record operating EBITDA of AUD 67M (+11%), but operating NPAT fell to AUD 23.2M from AUD 25.1M (down AUD 1.9M) due to faster-than-expected legacy loan runoff. The new Cashies Loan book grew nearly fivefold to over AUD 114M, with same-store sales rising 13% in Australia and 6% in the U.K., and management guided FY2027 revenue of 339.53 and FY2027 EPS of 0.03. Shares dropped 4.76% to $0.30 as investors weighed the NPAT decline alongside a 50% YoY cash fall to AUD 37.2M amid ongoing refinancing focus.

Analysis

The market is still pricing this as a transitional earnings miss, but the bigger mechanism is funding optionality. Once a lender is no longer carrying the old high-loss book, the equity value increasingly depends on whether management can re-open cheaper bank-style financing; that is a 6-12 month rerating event, not a one-quarter EPS story. The near-term selloff looks more like investors penalizing balance-sheet friction and execution risk than questioning the underlying franchise.

Second-order winners are the retail and resale peers exposed to cost-of-living pressure, because the business is proving that second-hand luxury and pawn-style inventory can take share without needing broad consumer discretionary strength. The more interesting loser set is smaller non-bank lenders that still rely on fragile wholesale funding; if this company gets a refinancing win, it validates that a de-risked product mix can lower funding costs across the sector. The flip side is that the new loan book is still young, so underwriting noise or a spike in unemployment would hit reported earnings before the strategic benefits show through.

Contrarian view: the consensus may be overemphasizing the NPAT decline and underestimating how much of the prior risk premium should compress if refinancing comes through. The key falsifier is not revenue growth; it is either a materially wider refinancing spread or evidence that the new loan product’s loss rate is not structurally better than the legacy book. In that scenario, the stock stays trapped as a low-quality small-cap financial, and any rerating is delayed by another 6-12 months.

Key Decisions for Investors

• Small starter long CCV on weakness, sized as a conditional catalyst trade for the next 1-3 months; thesis is refinancing/balance-sheet de-risking can re-rate the stock faster than earnings can. Add only if management gives concrete timing on facilities and the shares hold the recent low area; exit if refinancing slips or the new book loss rate deteriorates.
• Pair trade: long CCV / short HUM.ASX or another Australian non-bank lender with heavier funding dependence, for 3-6 months. CCV has a cleaner path to lower funding cost if the transition continues, while the short leg carries more direct sensitivity to wholesale credit spreads and provisioning pressure.
• Avoid chasing the name after an earnings drop; instead set a buy alert for a second washout into the lower end of the 52-week range. The risk/reward improves only if the market gives you a distressed entry before the refinancing catalyst.
• If you already own CCV, consider monetizing upside via covered calls into the next catalyst window rather than adding outright exposure. The stock can drift sideways until bank funding visibility improves, so premium capture may outperform directional beta here.